Internal Medicine Alert – June 30, 2022
June 30, 2022
View Issues
-
Beware the Cardiovascular Risks Associated with Thyroid Hormone Replacement Therapy
Thyroid levels outside the euthyroid range have been associated with higher cardiovascular risk in patients taking thyroid hormone to treat hypothyroidism. In this study, a higher cardiovascular mortality rate was associated with exogenous hyperthyroidism and exogenous hypothyroidism.
-
Recommendations Regarding Physical Activity to Delay Death
Using objective measurements of exercise intensity, researchers approximated 110,000 U.S. deaths/year could be prevented by a 10-minute daily increase in moderate-to-vigorous physical activity in adults age 40-85 years.
-
Regarding Exercise Capacity Past Age 75 Years, What Is Normal?
A group of researchers delivered results that could help inform clinicians about the expected exercise test performance of older patients.
-
HPV Vaccination in Adolescence Prevents Cancer More than 10 Years Later
In a study of human papillomavirus (HPV) vaccination, researchers evaluated cancer protection over up to 11 years of follow-up. During this time, the authors noted 100% vaccine efficacy at preventing HPV-associated cancers.
-
Mavacamten Capsules (Camzyos)
Mavacamten can be prescribed to adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.